Celgene licenses MorphoSys antibody for up to $818m
This article was originally published in Scrip
Celgene agreed to pay up to $818 million plus royalties to license and jointly develop the fully human monoclonal antibody MOR202 developed by MorphoSys to target CD38 for the treatment of multiple myeloma and certain leukemias.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.